Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel recombinant adenovirus vector having a reduced side effect

a technology of adenovirus and adenovirus gene, which is applied in the direction of viruses/bacteriophages, genetic material ingredients, dsdna viruses, etc., can solve the problems of inability to produce hd vectors in sufficient clinical applications, low vector productivity, and inability to maintain expression of transgenes, etc., to achieve the effect of enabling the persistence of transgene expression

Inactive Publication Date: 2009-04-23
SUMITOMO DAINIPPON PHARMA CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The solution effectively reduces inflammatory responses and enhances the productivity of adenovirus vectors, making them more suitable for clinical use by eliminating the need for helper viruses and maintaining persistent gene expression.

Problems solved by technology

Furthermore, it has been reported that in an adenovirus in which the E4 gene has been deleted, a moderate improvement was observed but was not satisfactory (Gao G-P. et al., J. Virol., 70: 8934-8943 (1996), Wang Q. et al., Gene Ther., 4: 393-400 (1997), and Dedieu J-F. et al., J. Virol., 71: 4626-4637 (1997)).
However, when this HD vector is clinically used as a pharmaceutical drug, there is a big problem of low productivity of vectors.
Furthermore, since the desired HD vector is always contaminated with the helper virus used for the production, the helper virus must be removed by separating the virus by ultracentrifugation based on a subtle difference in specific gravity between the viruses.
Therefore, to produce HD vectors in an amount sufficient for clinical applications is considered to be extremely difficult and is impractical.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel recombinant adenovirus vector having a reduced side effect
  • Novel recombinant adenovirus vector having a reduced side effect
  • Novel recombinant adenovirus vector having a reduced side effect

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction of a Human Growth Hormone-Expressing Adenovirus Vector

[0128](1) Cloning of Human Growth Hormone cDNA

[0129]In order to clone human growth hormone cDNA by the PCR method, the following procedure was carried out.

[0130]Phage DNAs were prepared from a commercial human pituitary adenoma-derived cDNA library (CLONTECH), and used as a template DNA for PCR. Primers for PCR were designed so as to add a recognition site for a restriction enzyme on both ends, and the 5′-end primer contained the initiation codon and a NheI recognition site, and the 3′-end primer contained the termination codon and a SphI recognition site. The sequence of each primer is shown below:

5′-end primer5-TGGCTAGCTCACCTAGCGGCAATGGCT-3′(SEQ ID NO: 1)     NheI               Met3′-end primer5-CAGGCATGCCACCCGGGCAGCTAGAA-3′(SEQ ID NO: 2)     SphI             End

[0131]Using the above-mentioned cDNA library-derived DNA as a template, polymerase pfu (Takara Shuzo) was used in a standard PCR reaction to thereby obtain...

example 2

Construction of an E2A Gene-Deleted Adenovirus Vector Expressing hGH

[0135](1) Construction of a Recombinant Adenovirus Vector for constructing an E2A-deleted adenovirus vector

[0136]The cosmid vector pAx2LD3LCAwt (pAdex2LD3LCAwt in Japanese Unexamined Patent Publication (Kokai) No. 8-308585, on page 19, is identical with pAx2LD3LCAwt) is a derivative of the above-mentioned cosmid vector pAxCAwt. pAx2LD3LCAwt is a cosmid in which loxP sites have been inserted between the adenovirus L3 gene and the E2A gene (61.5 map units), and in the deletion site (78.0 map units) of the E3 gene, and the nucleotide sequence other than the loxP insertion sites is identical with pAxCAwt.

[0137]After the plasmid pUCHGH constructed in Example 1 was digested with NheI and BglI, it was blunt-ended to obtain an about 0.7 kb DNA fragment containing the coding region of hGH cDNA. The DNA fragment was inserted into the SwaI site between the promoter and the poly(A) sequence of the cosmid vector pAx2LD3LCAwt to ...

example 3

Investigation of Inflammation-Inducing Effect of an E2A-Deleted Adenovirus Vector

[0157]In order to determine whether the deletion of the adenovirus E2A gene leads to reduction of the inflammation-inducing effect, the hGH-expressing E2A-deleted adenovirus vector (ΔE2A-CAHGH) or a hGH-expressing first generation adenovirus vector (Ax1CAHGH) were injected to mice, and the effect of inducing inflammation in both adenovirus vectors was compared with the serum GPT levels (glutamic pyruvic transaminase) as an index. The method and the result are shown below.

(1) Method

[0158]Mice used were C57BL / 6 mice (7-week old, female). The adenovirus vector used was ΔE2A-CAHGH (Lot 3) or Ax1CAHGH (Lot C). The dosage of the adenovirus vector was 1×109 PFU, 3×108 PFU, or 1×108 PFU (five animals per group), and an adenovirus vector diluted in saline was administered via the tail vein at 0.2 ml per mouse. Three days before, and 3, 5, 7, 10, 14, 21, 28, 35, 42, 49, 56, and 63 days after the administration of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector.

Description

[0001]This is a Continuation of application Ser. No. 10 / 296,716 filed Nov. 26, 2002, which is a National Stage application of PCT Application No. PCT / JP01 / 04360, filed May 24, 2001, which claims priority of Japanese Application Nos. JP 2000-155603, filed May 26, 2000, and JP 2000-373850, filed Dec. 8, 2000, the disclosure of each of which is incorporated herein by reference in its entirety.TECHNICAL FIELD[0002]The present invention relates to a recombinant adenovirus vector for gene therapy and a method for producing the vector. Specifically, the present invention relates to a novel recombinant adenovirus vector for which inflammation after in vivo administration thereof is alleviated by inhibiting the induction of the gene expression of adenovirus by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of said recombinant adenovirus vector, or a gene therapy method using said recombinant adenovirus vect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/00A61K48/00C12N15/861
CPCA61K48/00C12N15/86C12N2800/30C12N2710/10343C12N2710/10361C12N2710/10322C12N15/861
Inventor NAKAI, MICHIOKOMIYA, KAZUOMURATA, MASASHITOHDOH, NAOKISAITO, IZUMU
Owner SUMITOMO DAINIPPON PHARMA CO LTD